Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma.
Prolgolimab is an IgG1 anti-PD-1 mAb that contains the Fc-silencing LALA mutation, which provides an immunopotentiating advantage by abolishing the interaction between the Fcregion of the antibody and FcgR expressed on various immune cells, thus blocking the possible effector functions of the antibody[1].
References:
[1]. Tjulandin S, et, al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021 May;149:222-232.